Kenalog 40, 40 mg/ml suspension 1 ml 5 pcs

Pharmgroup:

Glucocorticosteroid.

Pharmic action:

Kenalog is a GCS. Suppresses the functions of leukocytes and tissue macrophages. Restricts the migration of leukocytes to the area of inflammation. Disrupts the ability of macrophages to phagocytosis, as well as the formation of interleukin-1.

It promotes stabilization of lysosomal membranes, thus reducing the concentration of proteolytic enzymes in the area of inflammation. Reduces capillary permeability caused by the release of histamine. It suppresses fibroblast activity and collagen formation.

Inhibits the activity of phospholipase A2, which leads to suppression of the synthesis of prostaglandins and leukotrienes. Suppresses the release of COX (mainly COX-2), which also helps to reduce the production of prostaglandins.

Decreases the number of circulating lymphocytes (T- and B-cells), monocytes, eosinophils and basophils due to their movement from the vascular bed to the lymphoid tissue; suppresses antibody formation.
Suppresses the release of ACTH and β-lipotropin by pituitary, but does not decrease circulating β-endorphin. Suppresses the secretion of TSH and FSH.

Pharmacokinetics:

When administered systemically, it is metabolized mainly in the liver and partially in the kidneys. The main metabolic pathway is 6-β-hydroxylation. It is excreted by the kidneys.

Indications

Systemic use of Kenalog (intravenous injection):
– hay fever;
– chronic obstructive respiratory diseases (e.g., bronchial asthma, chronic spastic bronchitis), with severe forms and negative results of local treatment;
– Skin diseases and contact dermatitis, characterized by itching, scaling or blistering, such as contact dermatitis, pemphigoid, psoriasis, dermatitis herpetiformis, atopic, exfoliative and eczematoid dermatitis.

Active ingredient

Composition

1 ml of the suspension for injection contains:

The active ingredient:

Triamcinolone acetonide 40.00 mg

The excipients:

Sodium carmellose 6.30 mg, sodium chloride 6.60 mg, benzyl alcohol 9.90 mg, polysorbate-80 0.40 mg, water for injection to 1.00 ml

How to take, the dosage

Kenalog is administered in m/m, in adults for systemic treatment – 1 ml (40 mg) slowly, deeply, intravenously, up to 80 mg (re-injection after 4 weeks).

For intrathecal administration (bursitis) to adults and children over 12 years of age, 10 to 40 mg.

The interval between injections is at least 2 weeks.

Injection under skin lesions dilute 1 ml with local anesthetic and administer 1 mg of the drug per 1 cm2 (not more than 30 mg per day in adults and 10 mg per day in children).

A second injection after 2 weeks.

Interaction

In systemic or repeated topical administration, the interactions typical for systemic therapy with glucocorticoids, which may weaken the hypoglycemic effect of antidiabetic drugs and the anticoagulative effect of coumarin derivatives, should be considered.

In concomitant use of the drug with cardiac glycosides, intensification of their action may be observed; when combined with saluretics, potassium excretion may increase.

Concomitant use with NSAIDs or antirheumatic drugs may contribute to gastrointestinal bleeding.

Concomitant use with rifampicin may decrease the corticoid effect of Kenalog.

Special Instructions

In case of systemic treatment with the drug, it is recommended to prescribe a diet enriched with proteins and vitamins.

For intravenous administration in the treatment of tendonitis, tendon sheath inflammation and “tennis elbow” it is recommended to use Kenalog 10 mg/ml.

In repeated use of the drug, injection intervals should be observed and, if necessary, injection intervals should be increased.

Contraindications

Hypersensitivity, gastric and duodenal ulcers, bone atrophy, mental diseases (including in anamnesis), viral diseases (herpes vesicularis, shingles), chickenpox, amebic and fungal infections, pediatric polio (except bulbar encephalitis form), glaucoma, age – from 12 to 16 years (intravenous administration).

Side effects

When systemic – moon-shaped face, Cushing’s syndrome, adrenal atrophy, muscle weakness, bone and muscle atrophy, diabetes, menstrual disorders, impotence, increased hair growth, bleeding from skin and mucous membranes, acne, potassium excretion, vasculitis, withdrawal syndrome, ulcerogenic effects, immune suppression, headaches, increased sweating, glaucoma, thrombosis.

Overdose

Symptoms: Icenko-Cushing’s syndrome, hyperglycemia, glucosuria.

Treatment: symptomatic with gradual withdrawal.

Pregnancy use

There are no data on the safety of Kenalog® 40 administration in pregnant women. When prolonged use of Kenalog® 40 by a pregnant woman, impairment of fetal intrauterine development cannot be excluded. If the drug is used at the end of pregnancy, there is a risk of fetal adrenal atrophy.

When using the drug during pregnancy (as well as in women of childbearing age outside of pregnancy), the anticipated benefit to the woman and the possible risk to the fetus must be weighed on a case-by-case basis.

The GKS in systemic use penetrate into the mother’s milk, so the anticipated benefit to the woman and the possible risk to the baby should be weighed in each case.

Similarities